Zacks Investment Research lowered shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a sell rating in a research report report published on Thursday.
According to Zacks, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “
Several other analysts also recently commented on CRSP. Cann reiterated a hold rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. SunTrust Banks restated a hold rating and set a $16.00 price target on shares of Crispr Therapeutics in a research report on Friday, November 10th. BidaskClub lowered shares of Crispr Therapeutics from a buy rating to a hold rating in a research report on Saturday, December 2nd. Oppenheimer initiated coverage on shares of Crispr Therapeutics in a research report on Thursday, December 7th. They set a hold rating for the company. Finally, Piper Jaffray Companies initiated coverage on shares of Crispr Therapeutics in a research report on Friday, December 22nd. They set an overweight rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $22.81.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.77) EPS. analysts expect that Crispr Therapeutics will post -2.42 earnings per share for the current fiscal year.
In related news, insider Tyler Dylan-Hyde sold 66,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the completion of the transaction, the insider now owns 25,204 shares in the company, valued at $706,468.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Thomas Woiwode sold 1,700 shares of the stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the transaction, the director now owns 8,218 shares of the company’s stock, valued at approximately $166,085.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,234,504 shares of company stock valued at $44,388,553. 39.98% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in Crispr Therapeutics during the third quarter valued at about $536,000. Hershey Trust Co. bought a new position in Crispr Therapeutics during the third quarter valued at about $768,000. Tiff Advisory Services Inc. bought a new position in Crispr Therapeutics during the third quarter worth about $505,000. Allianz Asset Management GmbH bought a new position in Crispr Therapeutics during the third quarter worth about $2,384,000. Finally, Granahan Investment Management Inc. MA boosted its position in Crispr Therapeutics by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after purchasing an additional 89,839 shares during the period. Institutional investors own 22.02% of the company’s stock.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.